Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease

Xinyu Yang, Xinxia Chang, Shengdi Wu, Xiaoyang Sun, Xiaopeng Zhu, Liu Wang, Yushan Xu, Xiuzhong Yao, Shengxiang Rao, Xiqi Hu, Mingfeng Xia, Hua Bian, Hongmei Yan, Xin GaoResearch 2021 · DOI

Introduction

Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health challenge, particularly among individuals with metabolic disorders like Type 2 Diabetes. The degree of liver fibrosis is the most significant prognostic factor for these patients, determining their long-term clinical outcomes. While liver biopsy remains the "gold standard" for staging fibrosis, its invasive nature and potential for sampling error have led to the widespread adoption of non-invasive alternatives. FibroScan, which measures liver stiffness (LSM) via transient elastography, is a leading tool in clinical practice. However, its accuracy can be influenced by extra-hepatic factors. This study investigates how abnormal glucose metabolism affects LSM readings in NAFLD patients.

Methods

This cross-sectional study included 91 patients with NAFLD and abnormal glucose metabolism (defined as fasting glucose ≥ 5.6 mmol/L or 2 h glucose ≥ 7.8 mmol/L) who underwent liver biopsy at Zhongshan Hospital, Fudan University. LSM was performed using the FibroScan M probe. The diagnostic performance of LSM was evaluated using receiver operator characteristic (ROC) curves, with biopsy results as the reference. Multivariate linear regression and subgroup analyses were conducted to identify metabolic indicators independently associated with LSM values after adjusting for histological findings like inflammation and ballooning.

Results

FibroScan demonstrated strong diagnostic performance, particularly for advanced stages of fibrosis. The area under the ROC curve (AUROC) for detecting cirrhosis (Stage 4) was 0.902, while the AUROC for Stage ≥3 was 0.837. The optimal cut-off values for stages ≥1, ≥2, ≥3, and 4 were 6.3 kPa, 7.6 kPa, 8.3 kPa, and 13.8 kPa, respectively.

A key finding was the impact of metabolic "noise" on these measurements. Multivariate analysis revealed that hemoglobin A1c (HbA1c) and aspartate aminotransferase (AST) were independently associated with LSM values, even after adjusting for histological fibrosis stage. Subgroup analysis showed that patients with poor glycemic control (HbA1c ≥ 7%) or obesity (BMI ≥ 30 kg/m²) exhibited higher LSM values regardless of actual scarring. For instance, the cut-off for significant fibrosis (Stage ≥2) shifted from 7.7 kPa in patients with well-controlled sugar (HbA1c < 7%) to 8.3 kPa in those with poor control (HbA1c ≥ 7%).

Discussion

The study confirms that while FibroScan is a valuable tool for evaluating liver fibrosis in NAFLD patients with glucose metabolism issues, its readings are not purely reflective of physical scarring. The independent association of HbA1c and AST with LSM suggests that metabolic state and active liver inflammation can artificially inflate stiffness readings. This "metabolic skew" is particularly relevant when diagnosing early-to-moderate fibrosis, where the margin for error is smaller. The increased distance ultrasound waves must travel in patients with higher BMI also likely contributes to signal attenuation and higher readings.

Conclusion

FibroScan is highly effective for ruling out advanced fibrosis and cirrhosis in NAFLD patients with abnormal glucose metabolism. However, clinicians must interpret LSM values within the context of the patient's metabolic profile. Future clinical guidelines may benefit from stratified cut-off values that account for HbA1c and BMI to improve diagnostic precision and facilitate personalized patient management.

Summary updated

Abstract

Abstract Background: The performance of liver stiffness measurements (LSMs) obtained using FibroScan can be affected by several factors, and cut-off values are different for fibrosis caused by various aetiologies. The study aims to evaluate the diagnostic accuracy of LSM in nonalcoholic fatty liver disease (NAFLD) patients with abnormal glucose metabolism and investigate whether the LSM value would be affected by metabolic indicators. Methods: The study involved 91 NAFLD patients with abnormal glucose metabolism who underwent liver biopsy. The diagnostic accuracy of LSM value was evaluated by the receiver operator characteristic (ROC) curves, with the biopsy results taken as the gold standard. Multivariate linear regression and subgroup analysis were performed to determine the correlated indicators. Results: The areas under the ROC curves (AUROCs) of LSM values for detecting fibrosis stage ≥1, 2, 3 and 4 were 0.793 (95% confidence interval [CI]: 0.695-0.871), 0.764 (95% CI: 0.663-0.846), 0.837 (95% CI: 0.744-0.906) and 0.902 (95% CI: 0.822-0.955), with cut-off values of 6.3, 7.6, 8.3 and 13.8 kPa, respectively. Multivariate linear regression demonstrated that haemoglobin A1c (HbA1c, β = 0.200, P = 0.038) and aspartate aminotransferase (AST, β = 0.200, P = 0.044) were independently associated with the LSM value after adjustment for fibrosis stage, ballooning and inflammation grade from liver biopsy. Subgroup analysis demonstrated that LSM values were slightly higher in patients with HbA1c ≥7% than in those with HbA1c &lt;7% and in patients with body mass index (BMI) ≥30 kg/m 2 than in those with BMI &lt;30 kg/m 2 . Conclusions: FibroScan was valuable for the evaluation of liver fibrosis in NAFLD patients with abnormal glucose metabolism. FibroScan is recommended to evaluate severe fibrosis, especially to exclude advanced fibrosis. Glucose metabolism state may affect LSM values.
BibTeX
@inproceedings{yang2021performance,
  author = {Xinyu Yang and Xinxia Chang and Shengdi Wu and Xiaoyang Sun and Xiaopeng Zhu and Liu Wang and Yushan Xu and Xiuzhong Yao and Shengxiang Rao and Xiqi Hu and Mingfeng Xia and Hua Bian and Hongmei Yan and Xin Gao},
  title = {{Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-139291/v2},
}
Figure